The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
DNA repair targeted therapy: The past or future of cancer treatment?
Open accessAbstract
The repair of DNA damage is a complex process that relies on particular pathways to remedy specific types of damage to DNA. The range of insults to DNA includes small, modest changes in structure including mismatched bases and simple methylation events to oxidized bases, intra- and interstrand DNA crosslinks, DNA double strand breaks and protein-DNA adducts. Pathways required for the repair of these lesions include mismatch repair, base excision repair, nucleotide excision repair, and the homology directed repair/Fanconi anemia pathway. Each of these pathways contributes to genetic stability, and mutations in genes encoding proteins involved in these pathways have been demonstrated to promote genetic instability and cancer. In fact, it has been suggested that all cancers display defects in DNA repair. It has also been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. This has led to targeting DNA repair pathways and proteins to develop anti-cancer agents that will increase sensitivity to traditional chemotherapeutics. While initial studies languished and were plagued by a lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interaction and develop high affinity chemical inhibitors have proven considerably more effective. In this review we will highlight recent advances and discuss previous failures in targeting DNA repair to pave the way for future DNA repair targeted agents and their use in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, S., Ren, T., Shan, J., Li, M., Qing, Y., Wang, G., Li, Q., Liu, G., Li, C., Yu, P., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s82724 · Cited by 31
RetractedSiegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Mechanism of Eukaryotic Homologous Recombination
San Filippo, J., Sung, P., & Klein, H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061306.125255 · Cited by 1,681
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
Chapman, J. R., Taylor, M. R. G., & Boulton, S. J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.029 · Cited by 1,625
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Chu, V. T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., & Kühn, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3198 · Cited by 1,210
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Strategies to improve radiotherapy with targeted drugs
Begg, A. C., Stewart, F. A., & Vens, C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3007 · Cited by 1,118
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 836
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635
DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities
Shibata, A., Moiani, D., Arvai, A. S., Perry, J., Harding, S. M., Genois, M.-M., Maity, R., van Rossum-Fikkert, S., Kertokalio, A., Romoli, F., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.003 · Cited by 567
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Griffin, R. J., Calvert, A. H., Newell, D. R., Smith, G. C. M., & Curtin, N. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4275 · Cited by 445
A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex
Dupré, A., Boyer-Chatenet, L., Sattler, R. M., Modi, A. P., Lee, J.-H., Nicolette, M. L., Kopelovich, L., Jasin, M., Baer, R., Paull, T. T., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.63 · Cited by 414
Collis, S. J., DeWeese, T. L., Jeggo, P. A., & Parker, A. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208332 · Cited by 412
Leahy, J. J. J., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Richardson, C., Rigoreau, L., & Smith, G. C. M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.060 · Cited by 411
Base excision repair: A critical player in many games
Wallace, S. S. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.030 · Cited by 401
Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F., Chong, W. Y., Hummersone, M., Rigoreau, L., Menear, K. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0519 · Cited by 385
Kitada, S., Leone, M., Sareth, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030190z · Cited by 379
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 373
The consequences of Rad51 overexpression for normal and tumor cells
Klein, H. L. (2008) · DNA Repair · doi:10.1016/j.dnarep.2007.12.008 · Cited by 356
Srivastava, M., Nambiar, M., Sharma, S., Karki, S. S., Goldsmith, G., Hegde, M., Kumar, S., Pandey, M., Singh, R. K., Ray, P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.11.054 · Cited by 355
Song, H., Dicks, E., Ramus, S. J., Tyrer, J. P., Intermaggio, M. P., Hayward, J., Edlund, C. K., Conti, D., Harrington, P., Fraser, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2408 · Cited by 328
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 321
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis
Andrabi, S. A., Umanah, G. K. E., Chang, C., Stevens, D. A., Karuppagounder, S. S., Gagné, J.-P., Poirier, G. G., Dawson, V. L., & Dawson, T. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405158111 · Cited by 307
Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited
Chiarugi, A. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01902-7 · Cited by 297
Chemotherapy induced DNA damage response: Convergence of drugs and pathways
Woods, D., & Turchi, J. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23761 · Cited by 296
Self-citationCancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Venkitaraman, A. R. (2014) · Science · doi:10.1126/science.1252230 · Cited by 289
Base Excision Repair and Lesion-Dependent Subpathways for Repair of Oxidative DNA Damage
Svilar, D., Goellner, E. M., Almeida, K. H., & Sobol, R. W. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3466 · Cited by 274
Wang, A. T., Kim, T., Wagner, J. E., Conti, B. A., Lach, F. P., Huang, A. L., Molina, H., Sanborn, E. M., Zierhut, H., Cornes, B. K., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.009 · Cited by 273
Willmore, E., de Caux, S., Sunter, N. J., Tilby, M. J., Jackson, G. H., Austin, C. A., & Durkacz, B. W. (2004) · Blood · doi:10.1182/blood-2003-07-2527 · Cited by 273
Beyond DNA Repair: DNA-PK Function in Cancer
Goodwin, J. F., & Knudsen, K. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0358 · Cited by 258
Elevated levels of Rad51 recombination protein in tumor cells.
Raderschall, E., Stout, K., Freier, S., Suckow, V., Schweiger, S., & Haaf, T. (2002) · PubMed · Cited by 254
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
Isolation of a small molecule inhibitor of DNA base excision repair
Madhusudan, S., Smart, F., Shrimpton, P., Parsons, J. L., Gardiner, L., Houlbrook, S., Talbot, D. C., Hammonds, T., Freemont, P. A., Sternberg, M. J. E., et al. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki781 · Cited by 238
Structure and conformational change of a replication protein A heterotrimer bound to ssDNA
Fan, J., & Pavletich, N. P. (2012) · Genes & Development · doi:10.1101/gad.194787.112 · Cited by 227
Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats
Sibanda, B. L., Chirgadze, D. Y., & Blundell, T. L. (2010) · Nature · doi:10.1038/nature08648 · Cited by 224
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M., Adams, B. R., Wagner, A. F., Khalil, A., Gilfor, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3408 · Cited by 213
Defective DNA Repair and Increased Genomic Instability in Artemis-deficient Murine Cells
Rooney, S., Alt, F. W., Lombard, D., Whitlow, S., Eckersdorff, M., Fleming, J., Fugmann, S., Ferguson, D. O., Schatz, D. G., & Sekiguchi, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021891 · Cited by 206
Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 202
Targeting ATR in DNA damage response and cancer therapeutics
Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.002 · Cited by 189
Wahba, L., Gore, S. K., & Koshland, D. (2013) · eLife · doi:10.7554/elife.00505 · Cited by 188
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
King, C., Diaz, H. B., McNeely, S., Barnard, D., Dempsey, J., Blosser, W., Beckmann, R., Barda, D., & Marshall, M. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1037 · Cited by 187
Qiao, G.-B., Wu, Y.-L., Yang, X.-N., Zhong, W.-Z., Xie, D., Guan, X.-Y., Fischer, D., Kolberg, H.-C., Kruger, S., & Stuerzbecher, H.-W. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602665 · Cited by 186
RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells
Budke, B., Logan, H. L., Kalin, J. H., Zelivianskaia, A. S., Cameron McGuire, W., Miller, L. L., Stark, J. M., Kozikowski, A. P., Bishop, D. K., & Connell, P. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks353 · Cited by 185
Daud, A. I., Ashworth, M. T., Strosberg, J., Goldman, J. W., Mendelson, D., Springett, G., Venook, A. P., Loechner, S., Rosen, L. S., Shanahan, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5027 · Cited by 185
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
Davidson, D. L., Amrein, L., Panasci, L., & Aloyz, R. S. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00005 · Cited by 180
Cardnell, R. J., Feng, Y., Diao, L., Fan, Y.-H., Masrorpour, F., Wang, J., Shen, Y., Mills, G. B., Minna, J. D., Heymach, J. V., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1975 · Cited by 178
Liu, J. F., Tolaney, S. M., Birrer, M., Fleming, G. F., Buss, M. K., Dahlberg, S. E., Lee, H., Whalen, C., Tyburski, K., Winer, E., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.020 · Cited by 174
Cisplatin Sensitizes Cancer Cells to Ionizing Radiation via Inhibition of Nonhomologous End Joining
Boeckman, H. J., Trego, K. S., & Turchi, J. J. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0032 · Cited by 170
Self-citationDysfunctional homologous recombination mediates genomic instability and progression in myeloma
Shammas, M. A., Reis, R. J. S., Koley, H., Batchu, R. B., Cheng, L., & Munshi, N. C. (2008) · Blood · doi:10.1182/blood-2007-05-089193 · Cited by 169
Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair
Chen, X., Zhong, S., Zhu, X., Dziegielewska, B., Ellenberger, T., Wilson, G. M., MacKerell, A. D., & Tomkinson, A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6636 · Cited by 168
Cellular radiosensitivity: How much better do we understand it?
Jeggo, P., & Lavin, M. F. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903261263 · Cited by 168
Andrš, M., Korábečný, J., Jun, D., Hodný, Z., Bártek, J., & Kuča, K. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501026z · Cited by 166
R. Kelley, M., M. Georgiadis, M., & L. Fishel, M. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010036 · Cited by 165
Toward specific functions of poly(ADP-ribose) polymerase-2
Yélamos, J., Schreiber, V., & Dantzer, F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.003 · Cited by 165
Cardnell, R. J. G., & Byers, L. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3391 · Cited by 165
Batey, M. A., Zhao, Y., Kyle, S., Richardson, C., Slade, A., Martin, N. M. B., Lau, A., Newell, D. R., & Curtin, N. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0707 · Cited by 164
CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy
McNeely, S., Beckmann, R., & Bence Lin, A. K. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.005 · Cited by 163
PARP-1 and PARP-2: New players in tumour development.
Yélamos, J., Farrés, J., Llacuna, L., Ampurdanés, C., & Martín‐Caballero, J. (2011) · Europe PMC (PubMed Central) · Cited by 155
Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks
Povirk, L. F. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.016 · Cited by 155
Papeo, G., Posteri, H., Borghi, D., Busel, A. A., Caprera, F., Casale, E., Ciomei, M., Cirla, A., Corti, E., D’Anello, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00680 · Cited by 147
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 147
PARP Inhibitor Development for Systemic Cancer Targeting
Zaremba, T., & Curtin, N. J. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007781668715 · Cited by 144
Hannay, J. A. F., Liu, J., Zhu, Q.-S., Bolshakov, S. V., Li, L., Pisters, P. W. T., Lazar, A. J., Yu, D., Pollock, R. E., & Lev, D. C. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0636 · Cited by 138
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M. N., O'Byrne, K. J., & Richard, D. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00086 · Cited by 138
Cellular Functions of Human RPA1
Haring, S. J., Mason, A. C., Binz, S. K., & Wold, M. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800881200 · Cited by 135
Wang, H., Wang, H., Powell, S. N., Iliakis, G., & Wang, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1289 · Cited by 130
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
Munck, J. M., Batey, M. A., Zhao, Y., Jenkins, H., Richardson, C. J., Cano, C., Tavecchio, M., Barbeau, J., Bárdos, J. I., Cornell, L., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0535 · Cited by 128
Rai, G., Vyjayanti, V. N., Dorjsuren, D. G., Simeonov, A. M., Jadhav, A., Wilson, D. M., & Maloney, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201537d · Cited by 123
Nucleotide Excision Repair in E. Coli and Man
Sancar, A., & Reardon, J. T. (2004) · Advances in protein chemistry · doi:10.1016/s0065-3233(04)69002-4 · Cited by 121
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma
Tennstedt, P., Fresow, R., Simon, R., Marx, A. H., Terracciano, L., Petersen, C., Sauter, G., Dikomey, E., & Borgmann, K. (2012) · International Journal of Cancer · doi:10.1002/ijc.27907 · Cited by 115
Anderson, V. E., Walton, M. I., Eve, P. D., Boxall, K. J., Antoni, L., Caldwell, J., Aherne, W., Pearl, L. H., Oliver, A. W., Collins, I., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1252 · Cited by 114
Rad51 supports triple negative breast cancer metastasis
Wiegmans, A. P., Al‐Ejeh, F., Chee, N., Yap, P.-Y., Gorski, J. J., Silva, L. M. D., Bolderson, E., Chenevix‐Trench, G., Anderson, R. L., Simpson, P. T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1923 · Cited by 111
Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776
Engelke, C. G., Parsels, L. A., Qian, Y., Zhang, Q., Karnak, D. M., Robertson, J. R., Tanska, D. M., Wei, D., Davis, M. A., Parsels, J. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3748 · Cited by 109
Pastwa, E., Neumann, R. D., Mezhevaya, K., & Winters, T. A. (2003) · Radiation Research · doi:10.1667/0033-7587(2003)159[0251:roridd]2.0.co;2 · Cited by 109
Overexpression of RAD51 occurs in aggressive prostatic cancer
Mitra, A., Jameson, C., Barbáchano, Y., Sánchez, L., Kote‐Jarai, Z., Peock, S., Sodha, N., Bancroft, E. K., Fletcher, A., Cooper, C., et al. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03448.x · Cited by 108
Alagpulinsa, D. A., Ayyadevara, S., & Reis, R. J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00289 · Cited by 105
Conte, G. D., Sessa, C., von Moos, R., Viganò, L., Digena, T., Locatelli, A., Gallerani, E., Fasolo, A., Tessari, A., Cathomas, R. L., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.345 · Cited by 104
Budke, B., Kalin, J. H., Pawłowski, M., Zelivianskaia, A. S., Wu, M., Kozikowski, A. P., & Connell, P. P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301565b · Cited by 104
Seto, T., Esaki, T., Hirai, F., Arita, S., Nosaki, K., Makiyama, A., Kometani, T., Fujimoto, C., Hamatake, M., Takeoka, H., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2234-6 · Cited by 104
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Zhu, J., Zhou, L., Wu, G., Koenig, H., Lin, X., Li, G., Qiu, X., Chen, C., Hu, C., Goldblatt, E. M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201760 · Cited by 100
Jordheim, L. P., Barakat, K., Heinrich, L., Matera, E., Cros‐Perrial, E., Bouledrak, K., Sabeh, R. E., Pérez, R., Wishart, D. S., Cohen, R., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.082347 · Cited by 99
Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human Tissue
Bhagwat, N. R., Roginskaya, V. Y., Acquafondata, M. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1237 · Cited by 95
Liu, Q., Jiang, H., Liu, Z., Wang, Y., Zhao, M., Hao, C., Feng, S., Guo, H., Xu, B., Yang, Q., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023427 · Cited by 94
Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death
Nagro, C. J. D., Xiao, Y., Rangell, L. K., Reichelt, M., & O’Brien, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.580159 · Cited by 91
Shuck, S. C., & Turchi, J. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3422 · Cited by 90
Self-citationRAD54 family translocases counter genotoxic effects of RAD51 in human tumor cells
Mason, J. M., Dusad, K., Wright, W. D., Grubb, J., Budke, B., Heyer, W., Connell, P. P., Weichselbaum, R. R., & Bishop, D. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv175 · Cited by 90
Carlessi, L., Buscemi, G., Larson, G., Hong, Z., Wu, J. Z., & Delia, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0567 · Cited by 89
RPA Inhibition Increases Replication Stress and Suppresses Tumor Growth
Glanzer, J. G., Liu, S., Wang, L., Mosel, A., Peng, A., & Oakley, G. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0306 · Cited by 88
Freschauf, G. K., Karimi‐Busheri, F., Ulaczyk‐Lesanko, A., Mereniuk, T. R., Ahrens, A., Koshy, J. M., Rasouli‐Nia, A., Pasarj, P., Holmes, C. F. B., Rininsland, F. H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1805 · Cited by 86
Karimi‐Busheri, F., Rasouli‐Nia, A., Allalunis‐Turner, J., & Weinfeld, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0480 · Cited by 83
Li, Y., Wang, X., Pan, Y., Lee, D., Chowdhury, D., & Kimmelman, A. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039588 · Cited by 83
ERCC1 and Non–Small-Cell Lung Cancer
Niedernhofer, L. J., Bhagwat, N. R., & Wood, R. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070742 · Cited by 79
Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
McNeil, E. M., Astell, K. R., Ritchie, A., Shave, S., Houston, D. R., Bakrania, P., Jones, H. M., Khurana, P., Wallace, C., Chapman, T., et al. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.002 · Cited by 79
Peddi, P., Loftin, C. W., Dickey, J. S., Hair, J. M., Burns, K. J., Aziz, K., Francisco, D., Panayiotidis, M. I., Sedelnikova, O. A., Bonner, W. M., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.033 · Cited by 77
Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells
Mathews, L., Cabarcas‐Petroski, S., Hurt, E. M., Zhang, X., Jaffee, E. M., & Farrar, W. L. (2011) · Pancreas · doi:10.1097/mpa.0b013e31821ae25b · Cited by 77
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2
Labroli, M. A., Paruch, K., Dwyer, M. P., Alvarez, C., Keertikar, K. M., Poker, C., Rossman, R. R., Duca, J. S., Fischmann, T. O., Madison, V., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.114 · Cited by 76
Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction
Barakat, K., Jordheim, L. P., Pérez, R., Wishart, D. S., Dumontet, C., & Tuszyński, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051329 · Cited by 73
Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
Mohammed, M., Vyjayanti, V. N., Laughton, C. A., Dekker, L. V., Fischer, P. M., Wilson, D. M., Abbotts, R., Shah, S., Patel, P. M., Hickson, I. D., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606058 · Cited by 72
DIDS, a chemical compound that inhibits RAD51-mediated homologous pairing and strand exchange
Ishida, T., Takizawa, Y., Kainuma, T., Inoue, J., Mikawa, T., Shibata, T., Suzuki, H., Tashiro, S., & Kurumizaka, H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp200 · Cited by 65
Sears, C. R., & Turchi, J. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.344911 · Cited by 65
Self-citationCalvo, E., Chen, V. J., Marshall, M. S., Ohnmacht, U., Hynes, S. M., Kumm, E., Diaz, H. B., Barnard, D., Merzoug, F. F., Huber, L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0114-5 · Cited by 63
Antolín, A. A., & Mestres, J. (2014) · Oncotarget · doi:10.18632/oncotarget.1814 · Cited by 62
Olaparib in the management of ovarian cancer
Bixel, K. L., & Hays, J. L. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s62809 · Cited by 60
DNA polymerase beta (pol β) inhibitors: A comprehensive overview
Barakat, K., Gajewski, M. M., & Tuszyński, J. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.008 · Cited by 59
Weiss, G. J., Donehower, R. C., Iyengar, T., Ramanathan, R. K., Lewandowski, K., Westin, E. H., Hurt, K. C., Hynes, S. M., Anthony, S. P., & McKane, S. W. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9815-9 · Cited by 59
Mishra, A. K., Dormi, S. S., Turchi, A. M., Woods, D. S., & Turchi, J. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.013 · Cited by 58
Self-citationLi, T., Christensen, S., Frankel, P. H., Margolin, K. A., Agarwala, S. S., Luu, T. H., Mack, P. C., Lara, P. N., & Gandara, D. R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9562-8 · Cited by 58
Abbotts, R., Jewell, R., Nsengimana, J., Maloney, D. J., Simeonov, A. M., Seedhouse, C., Elliott, F., Laye, J. P., Walker, C., Jadhav, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1926 · Cited by 57
DNA Polymerase β as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer
Jaiswal, A. S., Banerjee, S., Aneja, R., Sarkar, F. H., Ostrov, D. A., & Narayan, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016691 · Cited by 56
Jaiswal, A. S., Banerjee, S., Panda, H., Bulkin, C. D., Izumi, T., Sarkar, F. H., Ostrov, D. A., & Narayan, S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0309 · Cited by 55
Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors
Zhu, J., Chen, H., Guo, X. E., Qiu, X., Hu, C., Chamberlin, A. R., & Lee, W. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.021 · Cited by 53
Neher, T. M., Bodenmiller, D. M., Fitch, R. W., Jalal, S. I., & Turchi, J. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0303 · Cited by 53
Self-citationGrabauskiene, S., Bergeron, E. J., Chen, G., Chang, A. C., Lin, J., Thomas, D. G., Giordano, T. J., Beer, D. G., Morgan, M. A., & Reddy, R. M. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.010 · Cited by 50
Pal, J., Bertheau, R. C., Buon, L., Qazi, A. M., Batchu, R. B., Bandyopadhyay, S., Ali‐Fehmi, R., Beer, D. G., Weaver, D. W., Reis, R. J. S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.83 · Cited by 50
Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A
Frank, A. O., Vangamudi, B., Feldkamp, M. D., de Souza-Fagundes, E. M., Luzwick, J. W., Cortez, D., Olejniczak, E. T., Waterson, A. G., Rossanese, O. W., Chazin, W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401730y · Cited by 49
Caldwell, J., Welsh, E. J., Matijssen, C., Anderson, V. E., Antoni, L., Boxall, K. J., Urban, F., Hayes, A., Raynaud, F. I., Rigoreau, L. J. M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101150b · Cited by 49
Small-Molecule Inhibitors of APE1 DNA Repair Function: An Overview
Al-Safi, R. I., Odde, S., Shabaik, Y., & Neamati, N. (2011) · Current Molecular Pharmacology · doi:10.2174/1874467211205010014 · Cited by 48
A Small‐Molecule Protein–Protein Interaction Inhibitor of PARP1 That Targets Its BRCT Domain
Na, Z., Peng, B., Ng, S., Pan, S., Lee, J., Shen, H., & Yao, S. Q. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410678 · Cited by 46
DNA repair triggered by sensors of helical dynamics
Maillard, O., Camenisch, U., Clement, F. C., Blagoev, K. B., & Naegeli, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.08.008 · Cited by 45
Glanzer, J. G., Liu, S., & Oakley, G. G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.03.012 · Cited by 44
Zhao, H. W., Luoto, K. R., Meng, A. X., & Bristow, R. G. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.08.013 · Cited by 44
Andrews, B. J., & Turchi, J. J. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.385.3.4 · Cited by 44
Self-citationPawelczak, K. S., & Turchi, J. J. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.03.002 · Cited by 43
Self-citationGoglia, A. G., Delsite, R., Luz, A. N., Shahbazian, D., Salem, A. F., Sundaram, R. K., Chiaravalli, J., Hendrikx, P. J., Wilshire, J. A., Jasin, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0765 · Cited by 42
Kaur, G., Cholia, R. P., Mantha, A. K., & Kumar, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500865u · Cited by 42
Jaiswal, A. S., Panda, H., Law, B. K., Sharma, J. P., Jani, J. P., Hromas, R., & Narayan, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123808 · Cited by 41
Identification of Novel Small Molecule Inhibitors of the XPA Protein Using in Silico Based Screening
Neher, T. M., Shuck, S. C., Liu, J., Zhang, J., & Turchi, J. J. (2010) · ACS Chemical Biology · doi:10.1021/cb1000444 · Cited by 40
Self-citationIdentification and Characterization of Human Apurinic/Apyrimidinic Endonuclease-1 Inhibitors
Srinivasan, A., Wang, L., Cline, C. J., Xie, Z., Sobol, R. W., Xie, X., & Gold, B. I. (2012) · Biochemistry · doi:10.1021/bi300490r · Cited by 40
Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor
Wang, D., Li, M., Sui, J.-D., Ren, T., Li, Z., Zhang, L. N., Zhou, L., Cheng, Y., & Qian, C. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s62963 · Cited by 39
Doi, T., Yoshino, T., Shitara, K., Matsubara, N., Fuse, N., Naito, Y., Uenaka, K., Nakamura, T., Hynes, S. M., & Bence, A. K. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000278 · Cited by 37
Carlessi, L., Buscemi, G., Fontanella, E., & Delia, D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.06.002 · Cited by 36
Dorjsuren, D. G., Kim, D., Vyjayanti, V. N., Maloney, D. J., Jadhav, A., Wilson, D. M., & Simeonov, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047974 · Cited by 36
Duong, H., Hong, Y. B., Kim, J. S., Lee, H., Yi, Y. W., Kim, Y. J., Wang, A., Zhao, W., Cho, C., Seong, Y., et al. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12101 · Cited by 35
Concepts and Molecular Aspects in the Polypharmacology of PARP‐1 Inhibitors
Passeri, D., Camaioni, E., Liscio, P., Sabbatini, P., Ferri, M., Carotti, A., Giacchè, N., Pellicciari, R., Gioiello, A., & Macchiarulo, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500391 · Cited by 34
Glanzer, J. G., Carnes, K. A., Soto, P., Liu, S., Parkhurst, L. J., & Oakley, G. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1291 · Cited by 33
Lainchbury, M. D., Matthews, T. P., McHardy, T., Boxall, K. J., Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. K. D. H., Box, G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3012933 · Cited by 32
Irreversible Inhibition of DNA Polymerase β by Small-Molecule Mimics of a DNA Lesion
Arian, D., Hedayati, M. A., Zhou, H., Bilis, Z., Chen, K., DeWeese, T. L., & Greenberg, M. M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411733s · Cited by 26
Kruczynski, A., Barret, J.-M. M., van Hille, B., Chansard, N., Astruc, J., Menon, Y., Duchier, C., Créancier, L., & Hill, B. T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1305-2 · Cited by 21
Stachelek, G. C., Peterson-Roth, E., Liu, Y., Fernandez, R. J., Pike, L., Qian, J. M., Abriola, L., Hoyer, D., Hungerford, W. M., Merkel, J., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0036 · Cited by 19
Diphenylpyrazoles as Replication Protein A Inhibitors
Waterson, A. G., Kennedy, J. P., Patrone, J. D., Pelz, N. F., Feldkamp, M. D., Frank, A. O., Vangamudi, B., de Souza-Fagundes, E. M., Rossanese, O. W., Chazin, W., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5003629 · Cited by 18
Goldstein, L. J., Gurtler, J., Prete, S. A. D., Tjulandin, S., Семиглазов, В. Ф., Bayever, E., & Michiels, B. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.006 · Cited by 17
Mizushina, Y., Suzuki-Fukudome, H., Takeuchi, T., Takemoto, K., Kuriyama, I., Yoshida, H., Kamisuki, S., & Sugawara, F. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.12.038 · Cited by 16
Li, Y., Carty, M. P., Oakley, G. G., Seidman, M. M., Medvedovic, M., & Dixon, K. (2001) · Environmental and Molecular Mutagenesis · doi:10.1002/em.1020 · Cited by 16
Cited by
Molecular mechanisms of tumor resistance to radiotherapy
Wu, Y., Song, Y., Wang, R., & Wang, T. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01801-2 · Cited by 527
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 327
DNA Oxidation and Excision Repair Pathways
Lee, T.-H., & Kang, T.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236092 · Cited by 116
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Fifty years since DNA repair was linked to Cancer
Wood, R. D. (2018) · Nature · doi:10.1038/d41586-018-05255-1 · Cited by 9
Metadata
- Authors
- Gavande, N. S., VanderVere-Carozza, P. S., Hinshaw, H. D., Jalal, S. I., Sears, C. R., Pawelczak, K. S., & Turchi, J. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 160
- Pages
- 65-83
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2281629727
- Cited by
- 387
- References
- 165
- FWCI
- 21.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.